Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | PAPILLON Phase III primary results: amivantamab + chemo vs chemo in EGFR Exon 20 NSCLC

Nicolas Girard, MD, PhD, Institut Curie, Paris, France, discusses the primary results of the Phase III PAPILLON (NCT04538664) trial of amivantamab plus chemotherapy (ami-chemo) versus chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC). In the ami-chemo group, patients experienced a significantly longer progression-free survival (PFS) of 11.4 months compared to 6.7 months in the chemotherapy group. Ami-chemo also had a higher objective response rate (73% vs. 47%). The study demonstrated a favorable trend in overall survival for ami-chemo. The safety profile was in line with each individual agent, with 7% of patients discontinuing ami due to treatment-related adverse events. PAPILLON establishes ami-chemo as the new standard of care for first-line treatment in EGFR Ex20ins advanced NSCLC. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.